Immunomedics Inc

IMMU 
(NASDAQ) 
 
$ 14,94 <%= Resources.Global.txtUp %>
Opdateret 16-08-2019
Ændring % 3,97% Stigning i aktiekurs
Ændring 0,57 Stigning i aktiekurs
Volume 1.257.036
Høj $ 15,01
Lav $ 14,25
Åben $ 14,43
ISIN
Seneste luk $ 14,37
# af aktier 191,98M
Markedsværdi 2.868,16M USD
I dag

Market closed
Immunomedics Inc
Markedet er lukket, åbner klokken 15:30
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  14,94 -0,9% Fald i aktiekurs -2,4% Fald i aktiekurs -4,3% Fald i aktiekurs 5,0% Stigning i aktiekurs -28,9% Fald i aktiekurs
Powered by TradingView

Nyheder om Immunomedics Inc

  • Dansk
  • Engelsk
  • Fondsbørsmeddelelser

Firmaprofil

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. august 2019 09:44:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190809.4 - EUROWEB2 - 2019-08-18 09:44:39 - 2019-08-18 09:44:39 - 1 - Website: OKAY